The I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) is an ongoing multi-center, phase II, randomized trial (NCT01042379) testing anthracycline- and taxane-based NACT with or without pembrolizumab in patients with high-risk (by MammaPrint), stage II/III, HER2-negative BC. The gene discussed is ERBB2; the disease is breast cancer.